Feb. 9 at 5:07 PM
$ONCY Big Pharma's expanded M&A "sweet spot" becomes more relevant in the pelareorep acquisition picture.
As outlined,
$10 -
$15 Billion was Big Pharma's M&A "sweet spot" last year. This year in 2026 Big Pharma's "sweet spot" for biotech M&A deals have risen to the range of
$15 -
$20 Billion with a further premium for late-stage "platform/backbone" oncology assets that are scalable across multiple cancers, with unmet treatment needs.
The premium therefore, for ONCY's 'scarce' platform/backbone asset pelareorep, that Big Pharma inherently requires in their effort to enhance the effectiveness of their oncology pipelines, is in the range of 19$ - 24 Billion.
For context, the loss of Merck's
$29.5 Billion in Keytruda annual sales with Keytruda's LOE, is a major driver for Merck to come up with a way to extend Keytruda's lifecycle and their acquisition of ONCY's pelareorep is a straight forward way of maintaining and expanding their Keytruda 'franchise'.
